Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 146 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Sarcoidosis Clear all
Active, not recruiting No phase listed Observational

Medication Adherence in Patients With Sarcoidosis

NCT05438095
View directory record Official record
Conditions
Medication Adherence, Sarcoidosis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Timonium, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of CMK389 in Patients With Chronic Pulmonary Sarcoidosis

NCT04064242
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
CMK389, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Birmingham, Alabama • Gainesville, Florida • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2Phase 3 Interventional

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

NCT00794274
View directory record Official record
Conditions
Sarcoidosis, Cutaneous Sarcoidosis
Interventions
CC-100004
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

NCT04008069
View directory record Official record
Conditions
Sarcoidosis
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 4, 2023 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Jul 20, 2026, 7:20 PM EDT
Not yet recruiting No phase listed Observational

Exosome-based Omic Signatures of Disease Activity in Cardiac Sarcoidosis (EXODACS)

NCT07604220
View directory record Official record
Conditions
Cardiac Sarcoidosis, Sarcoidosis of the Heart, Sarcoidosis With Myocarditis, Sarcoidosis, Cardiac
Interventions
Exosome Analysis
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Patients With Pulmonary Sarcoidosis

NCT02888080
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
ACZ885, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
3
States / cities
Birmingham, Alabama • Albany, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional Results available

Phase II Investigation of Antimycobacterial Therapy on Progressive, Pulmonary Sarcoidosis

NCT02024555
View directory record Official record
Conditions
Sarcoidosis; Antimycobacterial Therapy
Interventions
Levofloxacin, Ethambutol, Azithromycin, Rifampin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
6
States / cities
Albany, New York • Cincinnati, Ohio • Cleveland, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 2 Interventional

A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis

NCT03727451
View directory record Official record
Conditions
Pulmonary Hypertension, Pulmonary Fibrosis, Sarcoidosis, Pulmonary
Interventions
iNO
Combination Product
Lead sponsor
Bellerophon
Industry
Eligibility
18 Years to 85 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
6
States / cities
Miami, Florida • Cincinnati, Ohio • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Not applicable Interventional

Diagnostic Yield of Vitreous Biopsy in Sarcoid Uveitis

NCT00609687
View directory record Official record
Conditions
Sarcoidosis-associated Ocular Inflammation
Interventions
Diagnostic Vitrectomy
Procedure
Lead sponsor
Duke University
Other
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Jul 20, 2026, 7:20 PM EDT
Not listed No phase listed Observational

Patient-Reported Outcome Study of Project ECHO for ILD

NCT05450276
View directory record Official record
Conditions
Interstitial Lung Disease
Interventions
Not listed
Lead sponsor
Pulmonary Care and Research Collaborative Limited
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 7, 2022 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational

Identifying Shared Genetic Susceptibility Regions in Chronic Beryllium Disease and Sarcoidosis

NCT00560989
View directory record Official record
Conditions
Sarcoidosis, Berylliosis
Interventions
Not listed
Lead sponsor
National Jewish Health
Other
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 25, 2014 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Not applicable Interventional Results available

Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis

NCT02546388
View directory record Official record
Conditions
Sarcoidosis
Interventions
Indium-111 Pentreotide, Gallium-68 DOTATATE
Drug
Lead sponsor
Marcelo F. Di Carli, MD, FACC
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Jul 20, 2026, 7:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Foundation for Sarcoidosis Research Advanced Cures Registry (FSR-SARC Registry)

NCT06234384
View directory record Official record
Conditions
Sarcoidosis
Interventions
Sarcoidosis diagnosis
Other
Lead sponsor
Foundation for Sarcoidosis Research
Other
Eligibility
7 Years and older
Enrollment
6,833 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2033
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational

PET Imaging in Patients With Suspected Cardiac Sarcoidosis

NCT03746847
View directory record Official record
Conditions
Cardiac Sarcoidosis
Interventions
Gallium-68 DOTATATE
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2022 · Synced Jul 20, 2026, 7:20 PM EDT
Enrolling by invitation Phase 2 Interventional

An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis

NCT06169397
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
XTMAB-16
Drug
Lead sponsor
Xentria, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
5
States / cities
Denver, Colorado • Chicago, Illinois • Greenville, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Not listed Phase 4 Interventional

Use of Roflumilast to Prevent Exacerbations in Fibrotic Sarcoidosis Patients (REFS)

NCT01830959
View directory record Official record
Conditions
Sarcoidosis
Interventions
Roflumilast, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 7, 2015 · Synced Jul 20, 2026, 7:20 PM EDT
Recruiting No phase listed Observational

Cardiovascular Multimodality Imaging Study

NCT06610019
View directory record Official record
Conditions
Non-ischemic Cardiomyopathy, Cardiomyopathies, Hypertrophic Cardiomyopathy, Right Ventricular Arrhythmogenic Cardiomyopathy, Cardiac Amyloidosis, Anderson Fabry Disease, Sarcoidosis, Cancer Therapy-related Cardiac Dysfunction, Ventricular Arrythmia, Heart Failure
Interventions
Not listed
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Salivary Proteins in Disease and Health

NCT00100204
View directory record Official record
Conditions
Diabetes Mellitus, Sarcoidosis, Dental Caries, Sjorgren's Syndrome, Cystinosis, Head and Neck Neoplasms
Interventions
Not listed
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
264 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 20, 2026, 7:20 PM EDT
Terminated Phase 4 Interventional Results available

Use of CXCL9 as a Biomarker of Acthar Efficacy

NCT02523092
View directory record Official record
Conditions
Sarcoidosis
Interventions
Acthar gel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Terminated Phase 3 Interventional

Mycophenolate for Pulmonary Sarcoidosis

NCT00262132
View directory record Official record
Conditions
Pulmonary Sarcoidosis
Interventions
Mycophenolate
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Jul 20, 2026, 7:20 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Rheumatology Patient Registry and Biorepository

NCT04402086
View directory record Official record
Conditions
Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases
Interventions
Not listed
Lead sponsor
Yale University
Other
Eligibility
18 Years to 99 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 20, 2026, 7:20 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

UTSW HP [13-C] Pyruvate Injection in HCM

NCT03057002
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Dilated Cardiomyopathy, Duchenne Muscular Dystrophy, Cardiac Sarcoidosis, Becker Muscular Dystrophy, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction
Interventions
Hyperpolarized 13C-Pyruvate
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 25, 2025 · Synced Jul 20, 2026, 7:20 PM EDT
Completed Phase 4 Interventional

Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension

NCT00403650
View directory record Official record
Conditions
Sarcoidosis, Pulmonary Arterial Hypertension
Interventions
Iloprost
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 11, 2013 · Synced Jul 20, 2026, 7:20 PM EDT